Summit Corp plc
Summit Corp plc is listed today as Summit Therapeutics Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2024 | $235 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Jun 2024 | $200 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Nov 2020 | $50 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Dec 2019 | $47 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Jan 2019 | $25 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| Mar 2014 | $12 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Summit Corp plc chose not to state its revenue in its newest notice of a funding round (Sep 2024).
SEC Form D · Sep 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Sep 2024
That is all the official record says: Summit Corp plc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Summit Corp plc are on record.
Investors#
No investor of Summit Corp plc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 13 investors.
Largest shareholders today
Institutions holding Summit Therapeutics Inc. shares, as of Sep 30, 2026.
- Baker Bros. Advisors LP$554 M4.10%
- BlackRock, Inc.$175 M1.30%
- FMR LLC$138 M1.02%
- Vanguard Capital Management LLC$122 M0.90%
- Vanguard Portfolio Management LLC$114 M0.84%
- State Street Corp$103 M0.76%
- Price T Rowe Associates Inc /MD/$90 M0.66%
- Citadel Advisors LLC$64 M0.47%
- Geode Capital Management, LLC$59 M0.44%
- Kynam Capital Management, LP$51 M0.38%
- UBS Group AG$50 M0.37%
- Two Sigma Investments, LP$38 M0.28%
- Bellevue Group AG$36 M0.26%
- D. E. Shaw & Co., Inc.$36 M0.26%
- AQR Capital Management LLC$33 M0.25%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Mahkam Zanganeh | Executive officer | Sep 2024 |
| Manmeet Soni | Executive officer | Sep 2024 |
| Robert Duggan | Executive officer | Sep 2024 |
| Camilla Johnathan Graham | Executive officer | Nov 2020 |
| David Johnathan Powell | Executive officer | Nov 2020 |
| Houbiers Paul Jos | Executive officer | Nov 2020 |
| Michael Paul Donaldson | Executive officer | Nov 2020 |
| Daniel W. Elger | Executive officer | Jan 2020 |
| David Roblin | Executive officer | Jan 2020 |
| Glyn Edwards | Executive officer | Jan 2020 |
| Raymond Spencer | Executive officer | Mar 2014 |
| Alessandra Cesano | Director | Sep 2024 |
| Jeff Huber | Director | Sep 2024 |
| Kenneth Clark | Director | Sep 2024 |
| Mahkam Zanganeh | Director | Sep 2024 |
| Manmeet Soni | Director | Sep 2024 |
| Mostafa Ronaghi | Director | Sep 2024 |
| Robert Booth | Director | Sep 2024 |
| Robert Duggan | Director | Sep 2024 |
| Yu Xia | Director | Sep 2024 |
| Ujwala Mahatme | Ms. Ujwala resigned as a director effective June 12, 2024 | Jun 2024 |
| Rainer Erdtmann | Director | Nov 2020 |
| Elaine W. Stracker | Director | Jan 2020 |
| Glyn Edwards | Director | Jan 2020 |
| Manmeet W. Soni | Director | Jan 2020 |
| Robert W. Duggan | Director | Jan 2020 |
| Ventzislav W. Stefanov | Director | Jan 2020 |
| David Wurzer | Director | Jan 2019 |
| Frank Armstrong | Director | Jan 2019 |
| Leopoldo Zambeletti | Director | Jan 2019 |
| Valerie Andrews | Director | Jan 2019 |
| Barry Price | Director | Mar 2014 |
| Jim Mellon | Director | Mar 2014 |
| Stephen Davies | Director | Mar 2014 |
Went public since 2015. Its SEC number is that of a company listed on a stock exchange.